How will eventual HIV cure impact prevention behavior?
Manya Magnus(Milken Institute), Amanda D. Castel(George Washington University), Judith Fenech, R. Strange, Nancy Patricia Caballero-Suárez(Instituto Nacional de Enfermedades Respiratorias), Cheriko A. Boone(George Washington University), Tiana Young(Community Education Group), J. Kanyinda(George Washington University), Emmanuel Sarkodie(Whitman-Walker Health), Tereza Cristina Scatena Villa(Universidade de São Paulo)
Cited by 0
Related Papers
Understanding Structural Barriers to Accessing HIV Testing and Prevention Services Among Black Men Who Have Sex with Men (BMSM) in the United States
|AIDS and Behavior|2014|303
Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061
|PLoS ONE|2013|196
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
|The Lancet HIV|2020|177
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
|PLoS Medicine|2018|173
Routine HIV Screening in the Emergency Department Using the New US Centers for Disease Control and Prevention Guidelines
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2007|169